Becton, Dickinson and Co. | BDX - Current Assets


Becton, Dickinson and Co. reported $8.32B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Abbott USD 23.5B 1.02B Sep/2026
Agilent USD 4.69B 70M Jun/2026
Align Technology USD 2.73B 63.03M Sep/2026
AngioDynamics USD 161.35M 4.69M Sep/2025
Baxter International USD 6.83B 163M Sep/2026
Becton, Dickinson and Co. USD 8.32B 178M Sep/2026
Bio-Rad Laboratories USD 3.08B 58.1M Sep/2026
Boston Scientific USD 8.16B 192M Sep/2026
Cooper Companies USD 2.28B 18.3M Jun/2026
Danaher USD 14.79B 1.41B Sep/2026
Dentsply International USD 1.98B 50M Sep/2026
Dexcom USD 3.92B 170.6M Sep/2026
Edwards Lifesciences USD 7.25B 428.6M Sep/2026
Globus Medical USD 2.18B 33.55M Sep/2026
Insulet USD 2.04B 192.4M Sep/2026
Integra LifeSciences USD 1.19B 1.54M Sep/2026
Intuitive Surgical USD 10.65B 1.68B Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Medtronic USD 24.39B 397M Jun/2026
Solventum Corp USD 3.69B 49M Sep/2026
Stryker USD 14.18B 235M Sep/2026
Tandem Diabetes Care USD 820.72M 16.08M Sep/2026
Teleflex USD 1.84B 31.2M Sep/2026
Terumo JPY 877.74B 28.86B Sep/2026
Thermo Fisher Scientific USD 25.62B 2.25B Sep/2026
Zimmer Biomet Holdings USD 5.13B 32.3M Sep/2026